미투 약물(Me Too Drug) 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 약제 클래스별, 치료 영역별, 지역별 세분화 및 경쟁 구도(2020-2030년
Me Too Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Therapeutic Area, By Region and Competition, 2020-2030F
상품코드:1879232
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 미투 약물(Me Too Drug) 시장은 2024년에 3억 8,481만 달러로 평가되었고, 2030년까지 연평균 복합 성장률(CAGR) 5.87%로 성장하여 5억 4,186만 달러에 이를 것으로 예측됩니다.
'미투' 의약품(후속 의약품 또는 점진적 혁신 화합물이라고도 함)은 기존 퍼스트 인 클래스 치료제와 구조적 유사성을 공유하는 약리학적 활성 물질이지만 특이성, 부작용, 약동학 등의 측면에서 차별화된 특성을 가질 수 있습니다. 이 시장 부문을 뒷받침하는 주요 요인은 확립된 치료 표적에 기반하여 R&D 리스크와 관련 비용을 줄이고, 보다 효율적인 의약품 개발 프로세스를 가능하게 한다는 점입니다. 또한, 이들 화합물은 기존 치료제 대비 치료 선택의 폭을 넓히고 유효성 및 안전성을 점진적으로 향상시켜 다양한 환자 니즈에 대응하고 있습니다.
The Global Me Too Drugs Market, valued at USD 384.81 Million in 2024, is projected to experience a CAGR of 5.87% to reach USD 541.86 Million by 2030. "Me Too" drugs, also recognized as follow-on or incremental innovation compounds, are pharmacologically active substances that share structural similarities with existing first-in-class treatments but may present differentiated profiles concerning specificity, adverse reactions, or pharmacokinetics. Key drivers supporting this market segment include the reduced research and development risk and associated costs stemming from validated therapeutic targets, enabling more streamlined drug development processes. These compounds also address varied patient requirements by offering therapeutic alternatives or incremental enhancements in efficacy and safety compared to established treatments.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 384.81 Million
Market Size 2030
USD 541.86 Million
CAGR 2025-2030
5.87%
Fastest Growing Segment
Statins
Largest Market
North America
Key Market Drivers
Patent expirations and intensified market competition are fundamental drivers for the global "me too" drugs market. When innovator drugs lose intellectual property protection, the market opens for other pharmaceutical firms to introduce similar compounds, often at more competitive prices, directly stimulating the development of follow-on products. For instance, according to GeneOnline News, in December 2024, Bristol Myers Squibb's leukemia treatment Sprycel, which garnered $1.45 billion in U. S. revenue in 2023, faced generic competition from September 2024, demonstrating the tangible commercial impact of exclusivity loss. This rivalry prompts companies to strategically develop "me too" drugs, leveraging validated targets and established therapeutic pathways to maintain market presence.
Key Market Challenges
The intensified regulatory scrutiny demanding clear demonstrations of clinical superiority and genuine patient benefit over existing marketed therapies presents a significant impediment to the growth of the global "Me Too" drugs market. This heightened examination directly complicates approval pathways and restricts subsequent market access for these compounds. Since "Me Too" drugs often offer incremental innovations, proving a substantial advantage over established treatments under rigorous regulatory frameworks necessitates extensive and costly clinical programs. This escalating requirement elevates the development risk, lengthens timelines, and increases the financial investment needed to bring such therapies to market.
Key Market Trends
The global "me too" drugs market is increasingly influenced by the pursuit of **Personalized Treatment Regimen Alignment**. This trend emphasizes tailoring therapies to individual patient characteristics, moving beyond a one-size-fits-all approach. By integrating genomic data and other biomarkers, pharmaceutical companies can develop follow-on drugs that offer enhanced efficacy or reduced side effects for specific patient subgroups, thereby commanding a differentiated market position. According to a MedCity News article published in February 2024, personalized medicine is transforming the role of pharmaceutical companies, requiring them to become service providers who assist healthcare providers with infrastructure, staff training, and precision diagnostics. The shift towards personalized medicine provides an avenue for "me too" drugs to demonstrate incremental clinical value by targeting unmet needs within defined patient populations.
Key Market Players
F. Hoffmann-La Roche AG
AstraZeneca PLC
Novartis AG
Sanofi S.A.
Eli Lilly and Company
Merck & Co., Inc.
Pfizer, Inc.
Gilead Sciences, Inc.
Bristol-Myers Squibb Company
AbbVie Inc.
Report Scope:
In this report, the Global Me Too Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Me Too Drugs Market, By Drug Class:
Beta Blockers
Antidepressants
Statins
Proton Pump Inhibitors
Benzodiazepines
Others
Me Too Drugs Market, By Therapeutic Area:
Oncology
Diabetes
Hepatitis C
Cardiovascular
Others
Me Too Drugs Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Me Too Drugs Market.
Available Customizations:
Global Me Too Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Me Too Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Beta Blockers, Antidepressants, Statins, Proton Pump Inhibitors, Benzodiazepines, Others)
5.2.2. By Therapeutic Area (Oncology, Diabetes, Hepatitis C, Cardiovascular, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Me Too Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Therapeutic Area
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Me Too Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Therapeutic Area
6.3.2. Canada Me Too Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Therapeutic Area
6.3.3. Mexico Me Too Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Therapeutic Area
7. Europe Me Too Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Therapeutic Area
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Me Too Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Therapeutic Area
7.3.2. France Me Too Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Therapeutic Area
7.3.3. United Kingdom Me Too Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Therapeutic Area
7.3.4. Italy Me Too Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Therapeutic Area
7.3.5. Spain Me Too Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Therapeutic Area
8. Asia Pacific Me Too Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Therapeutic Area
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Me Too Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Therapeutic Area
8.3.2. India Me Too Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Therapeutic Area
8.3.3. Japan Me Too Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Therapeutic Area
8.3.4. South Korea Me Too Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Therapeutic Area
8.3.5. Australia Me Too Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Therapeutic Area
9. Middle East & Africa Me Too Drugs Market Outlook
